The Role of Rituximab in the Treatment of Myasthenia Gravis
Table 1: Characteristics and Response to Rituximab Treatment in 53 Patients with Myasthenia Gravis Ref Age, MG Previous
MGFA CC Sex Type Treatments
25 27, M AChR+ S, ASTC, CA, I 26 9, F
AChR+ S, P, I, A 15 79, F AChR+ C, S
Immediately Before RTX
IVb IVb
Estimated III
RTX Given for Lymphoma 27 56, F MuSK+ S, I, P, A, M IVb
28 32, M MuSK+ S, A, P, I, CA, M, C
IVb V
Ab Titre Before RTX
55nM 7.3nM 12nM
NR NR
29 21, F MuSK+ S, I, P, A, M Estimated IVb NR 30 46, F AChR+ S, I, CA MuSK+ VGKC+
31 NR, F MuSK+ S, A, CA, M, P IVb 32 75, M AChR+ S, I, Mx
IIa
RTX Given for Lymphoma 33 50, F AChR+ S, Mx, A, I, P
RTX Given for Rheumatoid Arthritis 34 11, M AChR+ S, I, A, M
Estimated IIIb
247nM 89nM
422pM NR
> 8 U 15IU/ml Estimated IVb NR
After RTX Failure, Successfully Treated by ASCT 35 14, F AChR+ S, A, M, C, ASCT Estimated IVb NR
36 76, M AChR+ S, I, P VGKC+
37 71, M AChR+ P, Mx
RTX Given for Lymphoma 38 52, F MuSK+ S, A, CA, M,
C, I
54, F MuSK+ S, A, C, M, I 30, F MuSK+ S, I
50, M AChR+ S, A, C, I 31, F AChR+ S, A, C, M, I 73, F AChR+ S, A, I
Patient 4 Had a Malignant Thymoma 40 44, F AChR+ S, P
11, F AChR+ S, A, M NR, F NR
S, I, P
IVb V
IVb IVb IVb
Estimated IVb Estimated IVb
50nM 63nM
262nM
2,739nM 88nM
3.47nM 19.8nM
Estimated IIIb NR
Patients 1 and 3 Also Treated for a Malignant Thymoma 39 59, F MuSK+ S, I, A, C, P, M Estimated IVb NR
45, NR AChR+ S, A, C, P, M, I 27, NR MuSK+ S, A, C, P, M, I, CA
50, NR MuSK+ S, A, C, I
Estimated IVb NR Estimated IVb NR
Estimated IVb NR
41 32, F AChR+ S, A, CA, M, P Estimated IVb 75nM 45, F MuSK+ S, I, P 21, F AChR+ S, A
42 75, M AChR+ S, I 43 24, F AChR+ S, CA, M
Estimated IIIb NR Estimated IIb Estimated IIb
62, M MuSK+ S, A, Mx, CA, C Estimated IVb
36, M AChR+ S, CA, A, M Estimated IVb 31, F AChR+ S, I, M
Estimated IVb
Patient 3 Also Treated for a Malignant Thymoma 44 33, F MuSK+ S, M, P
38, F MuSK+ S, P, I
57, F MuSK+ S, A, CA, P 31, F MuSK+ S, P
53, F AChR+ S, A, P, I 55, F AChR+ S, A, P
EUROPEAN NEUROLOGICAL REVIEW BL x1/2
220nM NR
0.23nM
Estimated IVb >100nM 8.2nM
Estimated IVb 46nM
12, F AChR+ S, A, Mx, P, I, M Estimated IVb 212nM 19, M AChR+ S, A, P, CA, I
9.4nM
Estimated IIIa NR Estimated IIIa NR Estimated IVb NR Estimated IIIb NR Estimated IVb
Estimated IIIb NR
1g x2 BL BL BL BL BL BL
1.61nM
BL BL BL BL BL BL
BL BL
N N N
Y (9) Y (7) Y (7)
Y (5) Y (3) Y (3) Y (3) N N
Y (1) N
Y (2) Y (1) Y (2)
Y (3) Y (1) Y (4) Y (1) Y (3) Y (2)
48 24 24
24
NR NR
NR 33 27 24
NR NR 48 60 29 12 30
21 6
24 6
15 6
MM 16nM MM 0.6nM Im Im Im
CSR NR
MM NR MM NR
CSR CSR CSR
CSR
Undetectable Undetectable Undetectable
Undetectable
MM 110nM MM NR
MM 150nM MM NR
MM 0.39nM CSR I
D I I
60nM 3.6nM 9.3nM 350nM NR
MM NR Im
NR
MM NR MM NR
MM 0.19nM Im
NR 97 171nM
2,149nM 30nM
V
192IU/ml 235IU/ml
Estimated IVb 310nM IVb 7.5nM
Initial Dose Other of RTX
BL BL BL
BL BL
BL BL
NR BL
BL BL BL 1g x 2 BL BL
N N
Y (1)
Y (1) Y (1)
Y (1) N
N Y (7) Y (2) N
Y (2) N
Y (1) Y (2)
Cycles of RTX (n)
Follow-up Duration
Post-(first) RTX (months)
6
22 14
4 18
13 9
7 24 36 NR
25 18
14 9
MM 15nM MM 1.5nM Im
3.66nM
MM Undetectable CSR
NR CSR NR
MM Undetectable Undetectable Undetectable NR
Im MM 1.84U MM 6IU/ml W CSR CSR 10.77nM NR MM NR but +
undetectable 13nM
MM 2nM
MGFA PS Ab Titre After RTX
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108